utilities for pazopanib and placebo were from PALETTE. Lacking a connected evidence network, estimates of relative effectiveness for trabectedin and ifosfamide were from an unadjusted indirect treatment comparison vs. pazopanib. Costs were from NHS reference costs and other published sources. RESULTS: Compared with placebo, pazopanib is estimated to increase QALYs by 0.130 and costs by £8,072; the incremental cost effectiveness ratio (ICER) for pazopanib vs. placebo is estimated to be £63k/QALY gained. For most parameters, the ICER changed Ͻ30% with ϩ/Ϫ50% changes in the parameter value. Compared with trabectedin and ifosfamide, pazopanib provides equal or more QALYs at a lower cost. CONCLUSIONS: From a UK health care system perspective, pazopanib may not be cost-effective vs. placebo in patients with advanced/metastatic STS based on criteria typically used to evaluate therapies in the UK. Pazopanib may be cost-effective vs. trabectedin and ifosfamide, although there is substantial uncertainty associated with these comparisons.
OBJECTIVES:
The purpose of this study was to explore the cost-effectiveness of abiraterone acetate (abiraterone) vs. cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed after docetaxel from the Greek health care perspective. METHODS: As no head-to-head trial data were available for abiraterone versus cabazitaxel, an indirect cost-effectiveness model was developed using clinical data (progression free survival (PFS), overall survival (OS), adverse events (AEs)) from the pivotal Phase 3 clinical trials COU-AA-301 (abiraterone) and TROPIC (cabazitaxel). The basic assumption in the model was that both comparator arms in the trials were 'palliative' and therefore equivalent. Resource use, particularly for the management of AEs, was estimated based on data from Alexandra University Hospital in Athens. For validation purposes, a secondary analysis was conducted using UK resource use data. Both analyses used local 2012 costs, undiscounted. Costs of hospitalisation, day hospital visits, drug administration and laboratory tests were taken from officially published public tariffs. Drug acquisition costs came from the latest Price Bulletins. Since abiraterone and cabazitaxel are not yet marketed in Greece, respective prices were estimated based on available EU prices in April 2012. Calculations were based on the median treatment duration for each agent. RESULTS: Total treatment cost was lower for abiraterone (€25.847) compared to cabazitaxel (€26.648). Higher drug acquisition costs for abiraterone (€24.899 vs. €23.886 for cabazitaxel) were offset by lower administration costs (€844 vs. €2.292) and lower AE management costs (€104 vs. €470). The total treatment costs of abiraterone were €12.924 and €5.619 per incremental month of PFS and OS compared to palliative care, respectively; treatment costs for cabazitaxel were €19.034 and €11.103 per additional month of PFS and OS against palliative care, respectively. Results were validated by the secondary analysis. CONCLUSIONS: Abiraterone appears to be a potentially cost-effective option compared with cabazitaxel in the Greek health care setting. 
PCN85 ECONOMIC ASSESSMENT OF THE ONCOTYPE DX BREAST CANCER ASSAY

OBJECTIVES:
To perform an analysis, from a public financing viewpoint, of the economic impact and efficiency of the Oncotype DX (ODX) assay as a guide to providing chemotherapy to women with early breast cancer compared to guiding this decision using the Adjuvant! Online (AO) prognostic index. METHODS: Markov model was constructed to assess three alternatives: provision of chemotherapy to women with a high risk recurrence score (RS) (i.e., Ͼ30) with ODX, to women with an intermediate/high risk score (RS Ͼ18) and to those as indicated by the AO. For the base case, a price of €3200 was set for ODX plus €236.12 for treatment with tamoxifen for 6 months, plus €3490.50 for six cycles of chemotherapy. RESULTS: Mean cost associated with AO to guide the provision of chemotherapy was €8994.02 per patient, with ODX RS Ͼ30 as a guide was €11,521.56, and for RS Ͼ18 it was €12,070.03. The incremental cost effectiveness ratio for ODX RS Ͼ30 compared to AO was €9659.28 per QALY; for ODX RS Ͼ18 was €7105.80. When treatment was guided by AO, a mean of 16.80 QALYs were obtained per patient, ODX was associated with a mean 17.06 QALY with an RS of Ͼ30 and 17.13 QALY per with an RS of Ͼ18. In probablistic sensitivity analysis, assuming a willingness to pay of €10,000/ QALY, providing chemotherapy to patients with an ODX RS of Ͼ18 became the best alternative. Probability of this being the best choice was 60% for a willingness to pay of €20,000 /QALY and 70% for €30,000 /QALY. CONCLUSIONS: Compared to guiding the provision of chemotherapy with AO, the ODX would appear to be cost-effective. In the Spanish setting, for a willingness to pay €30,000/QALY, the best option would appear to be to prescribe chemotherapy for patients with ODX RS of Ͼ18.
PCN86
COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE FOR THE TREATMENT OF ADVANCED PROSTATE CANCER UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
native. Only direct medical costs were considered. Costs and outcomes were discounted at 5% yearly. The outcomes considered were life years (LY) and quality adjusted life years (QALY). RESULTS: The incremental cost-effectiveness analysis demonstrated that AA is the most economically attractive medication. When the incremental cost-effectiveness ratio (ICER) for LY and QALY gained was evaluated, AA was dominant with regards to C, being more effective (LY: 1.3559 vs 1.2895; QALY: 0.7977 vs 0.7329) with lower costs (R$79,974 vs R$90,025). CONCLUSIONS: AA is the best therapeutic option, with the best cost-effectiveness ratio, versus C for the treatment of patients diagnosed with advanced mCRPC under Brazilian private perspective. Mexico City, Mexico City, Mexico OBJECTIVES: To identify the cost effectiveness ratio of Vemurafenib in the treatment of patients of the public health care institutions in Mexico, with BRAF positive mutation (BRFAF ϩ) metastatic or advanced melanoma, compared with dacarbazina and temozolomide. METHODS: A Markov model was developed with monthly cycles, with 4 health states: clinical benefit, stable disease, disease progression and death, considering the adverse events as transitory stages, during a 5 year time horizon. A cost effectiveness analysis was developed, where the transition probabilities between the different health's states considered, are the basis to estimate how many life years (LY) the patients will achieve with the different treatment alternatives. The costing method used in this study is the direct medical costs, expressed in US dollars. RESULTS: In the pharmacoeconomic analysis, Vemurafenib was the most effective treatment producing a mean of 2.15 LY per patient during the 5 year time horizon, 1.17 additional LY to those produced by dacarbazine (.98 LY) or temozolomide (0.98 LY). This shows that Vemurafenib is the most effective alternative for this patient due the effectiveness is 2.2 times higher compared to dacarbazine and temozolomide. CONCLUSIONS: Given the current worldwide discussion regarding the cost-effectiveness (CE) of orphan drugs, is considered necessary to evaluate these drugs under a different criteria that those used for drugs that are not orphans. So patients, who have rare and deadly diseases, can have the opportunity to live longer and better. 
PCN87 COST EFFECTIVENESS EVALUATION OF VEMURAFENIB, AN ORPHAN DRUG FOR BRAF MUTANT METASTATIC MELANOMA
Alva M 1 , Gay JG 2 , Sanchez Kobashi R 3 1 Roche Mexico, Mexico City, Mexico, 2 T.I. Salud, Mexico, Mexico City, Mexico, 3 T.I. Salud,
PCN88
COST-EFFECTIVENESS ANALYSIS PER LIFE-YEAR GAINED BASED ON PREDICTORS OF RESPONSE FOR FIRST LINE METASTASIC COLORECTAL CANCER THERAPY IN SPAIN
OBJECTIVES:
To perform a cost-effectiveness analysis based on markers of response/resistance including biological therapies available in Spain for metastasic colorectal cancer (mCRC). METHODS: Incremental cost-effectiveness ratio (ICER) per life-year gained (LYG) and progression-free year gained were calculated based on predictive markers for mCRC. Efficacy data include randomized trials (RT) that guided on-label uses of bevacizumab and cetuximab. Control arms from these trials were used as reference scenario. Markers of clinical benefit (biological & radiological) were included. Toxicity as predictor of efficacy was excluded for any therapy. Prices for drugs in Spain were assumed to represent the best-value for each drug including all possibilities to reduce pharmacy costs. For 1st line, median duration of therapy reported by RT was used to calculate the final budget. 70kg and 1.7 m were used as reference for patients dose calculations. If accessible, HR for PFS and OS were used instead of medians. RESULTS: K-Ras status and early response measured by computed tomography at 8 weeks were used as predictors of resistance and increased efficacy for cetuximab-based combinations. We have not identified any predictor marker for other drugs from RT. In this regard, FOLFIRIϩcetuximab combination obtained an ICER below the widely-proposed Spanish threshold of 30,000 € per LYG if patients harbored wild type (wt) K-Ras tumors and evidenced an objective response at 8 weeks. Other ICERs for different schedules were too distant from this limit. Multivariate analysis confirmed the robustness of results. CONCLUSIONS: First-line FOLFIRIϩcetuximab therapy for wt K-Ras patients that get an objective response measured by CT at 8 weeks is the only cost-effective therapy option for mCRC below usual health economics thresholds for Spain. Our results are critical to design cost-effectiveness based clinical guidelines for mCRC that will contribute to financial sustainability of public health system in Spain.
PCN89 COST EFFECTIVENESS OF TREATMENT WITH NEW 6-MONTH LEUPRORELIN ACETATE FORMULATION IN PATIENTS WITH ADVANCED PROSTATE CANCER
Tundia NL 1 , Fuldeore M 2 , Gruca D 3 , Hass S 2 , Bacher P 2 , Bodhani A 2 1 University of Cincinnati, Cincinnati, OH, USA, 2 Abbott Laboratories, Abbott Park, IL, USA, 3 Abbott Laboratories, Ludwigshafen, Germany OBJECTIVES: To conduct a cost effectiveness analysis (CEA) comparing 3.75 mg 1-month (1M), 11.25 mg 3-month (3M) and 30 mg 6-month (6M) leuprorelin acetate formulations (LAF) in patients with advanced prostate cancer (APC) in Switzerland. METHODS: A CEA was performed from the payer perspective using a decision-tree model. Total treatment costs per patient per year and cost-effectiveness ratios (CER) were calculated. Clinical efficacy and safety data (serum testosterone Ͻ50ng/dl and adverse drug reactions /ADRs/) for LAF were obtained from randomized trials. Direct medical costs (drug, physician consultation and drug administration, and ADRs), reported as 2011 in Swiss Francs (CHF), were obtained from a Swiss health care database (Tarmed) and doctor interviews. We assumed a patient would visit the physician's office a minimum of 12, 4 and 2 times/year when treated with 1M, 3M and 6M LAF, respectively. The modeled annual costs were extrapolated to the median survival time (3.1 years) of a patient with APC. One and twoway sensitivity analysis was conducted to check robustness of the model. RESULTS: In Switzerland, the annual cost associated with 6M LAF (CHF 3,320) was lower than that associated with 3M (CHF 4,411) and 1M (CHF 5,672) LAF. The lifetime costs of treatment with 1M, 3M and 6M LAF were CHF 16, 349, CHF 12, 715 and CHF 9, 664, respectively (Discount rateϭ3%) . Annual cost savings associated with the 6M formulation were 41% and 24% over the 1M and 3M formulations, respectively. 1M and 3M LAF were dominated with higher overall costs and lower effectiveness compared to the 6M formulation (CERϭCHF 5,154/effectiveness). Sensitivity analysis confirmed the robustness of the results. CONCLUSIONS: Results suggest 6M LAF as a cost-effective strategy for treating patients with APC. Dosing frequency, reduction of possible local side reactions and number of outpatient visits could be potential factors in optimizing drug-related treatment costs for APC. (2011 values). The model time horizon was 10 years and monthly cycles were used. Annual discounting of 4%/1,5% was applied on costs and effects, respectively. RESULTS: The analysis showed that patients with bendamustine and chlorambucil as first line treatment generated 3.77 and 2.21 QALYs, respectively. The total average costs amounted to €79,328 for bendamustine, and €67,172 for chlorambucil. The incremental cost effectiveness ratio (ICER) of bendamustine compared to chlorambucil was €7,809 per QALY gained. The incremental cost per LY and PFLY gained were €7,374 and €6,908. The costeffectiveness acceptability curve indicated that the probability that bendamustine was cost-effective approximated 95% at a threshold of €20,000 per QALY. CONCLUSIONS: Bendamustine compared to chlorambucil, in previously untreated Binet B or C CLL patients for whom fludarabine combination therapy is not appropriate, generated an ICER of €7,809 per QALY gained. This indicated that bendamustine is cost-effective as first line treatment for CLL in the Netherlands.
PCN90 COST EFFECTIVENESS ANALYSIS OF BENDAMUSTINE AS FIRST LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE NETHERLANDS
